NEW YORK, May 8, 2006 (PRIMEZONE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) announced today it has accepted invitations to participate in three upcoming scientific meetings focused on obesity and related disorders. The events are:
-- ENDO 2006 -- The Endocrine Society's 88th Annual Meeting
Boston Convention & Exhibit Center, Boston, MA
June 24-27, 2006
Poster presentation titled: Effect of Chronic or Intermittent Oral
Administration of Oleoyl-estrone on Food Intake, Body Weight and Body
Composition in Normal Rats
-- 2nd Annual Obesity Drug Development Summit
Ritz Carlton Hotel, Tyson's Corner, VA
July 27-28, 2006
Presentation titled: Oral Oleoyl-estrone -- A Novel Small Molecule
for the Treatment of Obesity
-- 10th International Congress on Obesity
Sydney Convention & Exhibition Centre, Sydney, Australia
September 3-8, 2006
Poster presentation titled: Long-Term Treatment of Zucker Obese Rats
with Oleoyl-estrone Decreases the Expression of Pro-inflammation
Markers in White Adipose Tissue
Poster presentation titled: Pair-Feeding and Oleoyl-estrone Treatment
of Lactating Rat Dams Affects Differentially the Growth of Their
Offspring
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc., a development stage pharmaceutical company, acquires and develops proprietary prescription drug candidates for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (http://www.manhattanpharma.com)
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion and results of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, issues relating to drug formulation and manufacturing, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2005.